These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Parravano M; Menchini F; Virgili G Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414 [TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741 [TBL] [Abstract][Full Text] [Related]
9. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis. Zhou S; Gao J; Xu X Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277 [TBL] [Abstract][Full Text] [Related]
10. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395 [TBL] [Abstract][Full Text] [Related]
11. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
12. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Yilmaz T; Cordero-Coma M; Gallagher MJ; Teasley LA Acta Ophthalmol; 2011 Dec; 89(8):709-17. PubMed ID: 20645926 [TBL] [Abstract][Full Text] [Related]
14. The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema. Jakobsen NS; Larsen DA; Bek T Acta Ophthalmol; 2018 Nov; 96(7):744-748. PubMed ID: 29687595 [TBL] [Abstract][Full Text] [Related]
15. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Cai S; Bressler NM Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425 [TBL] [Abstract][Full Text] [Related]
17. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology. Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA; JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939 [TBL] [Abstract][Full Text] [Related]
19. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Wu L; MartÃnez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ; Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014 [TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]